Anti-Xa activity of enoxaparin and nadroparin in patients with acute coronary syndrome

Experimental and Clinical Cardiology

Volumn 13, Issue 4, 2008, Pages 175-178

  Ostadal, Petr ^a   Alan, David ^a   Vejvoda, Jiri ^a   Segethova, Jitka ^a   Kruger, Andreas ^a  

^a UNIVERSITY HOSPITAL MOTOL   (Czech Republic)

Author keywords

Acute coronary syndrome; Enoxaparin; Factor Xa; Heparin; Nadroparin

Indexed keywords

BLOOD CLOTTING FACTOR 10A; ENOXAPARIN; NADROPARIN; TROPONIN;

ACUTE CORONARY SYNDROME; ADULT; AGED; ANTICOAGULATION; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMOGRAPHY; DIABETES MELLITUS; DISEASE CLASSIFICATION; DRUG EFFICACY; FEMALE; HUMAN; HYPERLIPOPROTEINEMIA; HYPERTENSION; MALE; PERCUTANEOUS CORONARY INTERVENTION; POSTOPERATIVE CARE; PROGNOSIS; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; RECOMMENDED DRUG DOSE; SMOKING;

EID: 63449087956     PISSN: 12056626     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Cohen M, Demers C, Gurfinkel EF, et al. Low-molecular-weight heparins in non-ST-segment elevation ischemia: The ESSENCE trial. Efficacy and Safety of Subcutaneous Enoxaparin versus intravenous unfractionated heparin, in non-Q-wave Coronary Events. Am J Cardiol 1998;82:19L-24L.
2. Antman EM, McCabe CH, Gurfinkel EP, et al. Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) 11B trial. Circulation 1999;100:1593-1601.
3. Ferguson JJ, Califf RM, Antman EM, et al. Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: Primary results of the SYNERGY randomized trial. JAMA 2004;292:45-54.
4. Ross AM, Molhoek P, Lundergan C, et al. Randomized comparison of enoxaparin, a low-molecular-weight hepatin, with unfractionated heparin adjunctive to recombinant tissue plasminogen activator thrombolysis and aspirin: Second trial of Heparin and Aspirin Reperfusion Therapy (HART II). Circulation 2001;104:648-52.
5. Cohen M, Theroux P, Borzak S, et al. Randomized double-blind safety study of enoxaparin versus unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes treated with tirofiban and aspirin: The ACUTE II study. The Antithromboric Combination Using Tirofiban and Enoxaparin. Am Heart J 2002;144:470-7.
6. Cohen M, Gensini GF, Maritz F, et al. The safety and efficacy of subcutaneous enoxaparin versus intravenous unfractionated heparin and tirofiban versus placebo in the treatment of acute ST-segment elevation myocardial infarction patients ineligible for reperfusion (TETAMI): A randomized trial. J Am Coll Cardiol 2003;42:1348-56.
7. Goodman SG, Fitchett D, Armstrong PW, Tan M, Langer A. Randomized evaluation of the safety and efficacy of enoxaparin versus unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes receiving the glycoprotein IIb/IIIa inhibitor eptifibatide. Circulation 2003;107:238-44.
8. Comparison of two treatment durations (6 days and 14 days) of a low molecular weight heparin with a 6-day treatment of unfractionated heparin in the initial management of unstable angina or non-Q wave myocardial infarction: FRAX.I.S. (FRAxiparine in Ischaemic Syndrome). Eur Heart J 1999;20:1553-62.
9. Samama MM, Gerotziafas GT. Comparative pharmacokinetics of LMWHs. Semin Thromb Hemost 2000;26(Suppl 1):31-8.
10. Okmen E, Ozen E, Uyarel H, Sanli A, Tartan Z, Cam N. Effects of enoxaparin and nadroparin on major cardiac events in high-risk unstable angina treated with a glycoprotein IIb/IIIa inhibitor. Jpn Heart J 2003;44:899-906.
11. Shafiq N, Malhotra S, Pandhi P, Sharma N, Bhalla A, Grover A. A randomized controlled clinical trial to evaluate the efficacy, safety, cost-effectiveness and effect on PAI-1 levels of the three low-molecular-weight heparins - enoxaparin, nadroparin and dalteparin. The ESCAPe-END study. Pharmacology 2006;78:136-43.
12. Gurfinkel FF, Perel C, Pombo G. Nadroparine calcium or enoxaparine in acute coronary syndrome patients suffering renal insufficiency: The nadroparin versus enoxaparin (NaVe) study design. Thromb J 2004;2:6.
13. Batchelor WB, Mahaffey KW, Berger PB, et al. A randomized, placebo-controlled trial of enoxaparin after high-risk coronary stenting: The ATLAST trial. J Am Coll Cardiol 2001;38:1608-13.
14. Daoulah A, Segev A, Leblanc K, Chisholm RJ, Strauss BH. Postprocedural low molecular weight heparin in patients at high risk of subacute stent thrombosis. Cardiovasc Radiat Med 2003;4:182-5.
15. Silber S, Albertsson P, Aviles FF, et al. Guidelines for percutaneous coronary interventions. The Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology. Eur Heart J 2005;26:804-47.
16. Smith SC Jr, Feldman TE, Hirshfeld JW Jr, et al. ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update the 2001 Guidelines for Percutaneous Coronary Intervention). J Am Coll Cardiol 2006;47:e1-121.
17. Montalescot G, Collet JP, Tanguy ML, et al. Anti-Xa activity relates to survival and efficacy in unselected Acute coronary syndrome patients treated with enoxaparin. Circulation 2004;110:392-8.
18. Petersen JL, Mahaffey KW, Hasselblad V, et al. Efficacy and bleeding complications among patients randomized to enoxaparin or unfractionated heparin for antithrombin therapy in non-ST-Segment elevation acute coronary syndromes: A systematic overview. AMA 2004;292:89-96.
19. Baird SH, Menown IB, McBride SI, Trouton TG, Wilson C. Randomized comparison of enoxaparan with unfractionated heparin following fibrinolytic therapy for acute myocardial infarction. Eur Heart J 2002;23:627-32.